For the quarter ending 2025-09-30, AGL had $268K increase in cash & cash equivalents over the period. -$21,329K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -110,207 | -92,258 |
| Depreciation and amortization | 7,430 | 14,195 |
| Stock-based compensation expense | 7,498 | 32,101 |
| Loss (income) from equity method investments | 13,133 | 18,084 |
| Distributions of earnings from equity method investments | 0 | 0 |
| Adjustments on sale of assets, net | 0 | 14,000 |
| Other noncash items | 2,464 | 3,107 |
| Changes in operating assets and liabilities | -92,722 | -14,081 |
| Net cash provided by (used in) operating activities | -18,154 | -67,072 |
| Purchase of property and equipment | 3,175 | 7,099 |
| Purchase of intangible assets | 13,359 | 9,717 |
| Investment in loans receivable and other | 0 | 1,000 |
| Investments in marketable securities | 0 | 60,154 |
| Proceeds from maturities of marketable securities and other | 35,192 | 125,339 |
| Net cash provided by (used in) investing activities | 18,658 | 47,369 |
| Proceeds from (payments for) equity issuances, net | -236 | -2,741 |
| Repayments of long-term debt | 0 | 0 |
| Net cash provided by (used in) financing activities | -236 | -2,741 |
| Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents | 268 | -22,444 |
| Cash and cash equivalents at beginning of period | 193,860 | - |
| Cash and cash equivalents at end of period | 171,684 | - |
agilon health, inc. (AGL)
agilon health, inc. (AGL)